UPDATE - UBS initiates coverage on Gevo (GEVO) with a Neutral; Renewable Opportunity
Tweet
Share
E-mailGet Alerts GEVO Hot Sheet
Price: $1.54 +1.99%
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
UPDATE - UBS initiates coverage on Gevo (Nasdaq: GEVO) with a Neutral. PT $21.
UBS analyst says, "Gevo is commercializing bio-isobutanol made from corn. It is focused on first producing highly demanded chemical intermediates such as isobutylene; fuel markets will come next. Through 2015, only low single digit penetration is needed to execute on plan for its large addressable markets for various chemical (~$10B) and fuel (>$150B) applications. Its IP/tech advantage - it has demonstrated a 94% yield (higher than its most significant peer)--should keep operating expenses low while making for attractive economics for partners and customers alike."
"We initiate at Neutral given valuation and as we await achievement of certain milestones, including: 1) conversion of existing LOIs into contracts; 2) on-schedule retrofit of plant #1 (first isobutanol sales in 1H12); 3) additional LOIs signed; 4) new customer acquisitions. We believe progress on these de-risking events would increase shareholder value."
To see all upgrades/downgrades on shares of GEVO, visit our Analyst Ratings page.
UBS analyst says, "Gevo is commercializing bio-isobutanol made from corn. It is focused on first producing highly demanded chemical intermediates such as isobutylene; fuel markets will come next. Through 2015, only low single digit penetration is needed to execute on plan for its large addressable markets for various chemical (~$10B) and fuel (>$150B) applications. Its IP/tech advantage - it has demonstrated a 94% yield (higher than its most significant peer)--should keep operating expenses low while making for attractive economics for partners and customers alike."
"We initiate at Neutral given valuation and as we await achievement of certain milestones, including: 1) conversion of existing LOIs into contracts; 2) on-schedule retrofit of plant #1 (first isobutanol sales in 1H12); 3) additional LOIs signed; 4) new customer acquisitions. We believe progress on these de-risking events would increase shareholder value."
To see all upgrades/downgrades on shares of GEVO, visit our Analyst Ratings page.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DA Davidson Starts Everus (ECG) at Buy
- D. Boral Capital Starts Eve Holding Inc. (EVEX) at Buy
- Keefe, Bruyette & Woods Resumes Bank of Montreal (BMO:CN) (BMO) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
